Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome

[1]  T. Investigators.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[2]  E. Topol.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.

[3]  Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. , 1998, The New England journal of medicine.

[4]  Gebhardt,et al.  International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina , 1998 .

[5]  P. T. Onundarson,et al.  Activated and total coagulation factor VII, and fibrinogen in coronary artery disease. , 1998, Scandinavian cardiovascular journal : SCJ.

[6]  N. Wenger,et al.  Coronary heart disease: an older woman's major health risk , 1997, BMJ.

[7]  J. Feldman,et al.  Health, United States, 1996-97 and Injury chartbook , 1997 .

[8]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[9]  P. Bray,et al.  Gender Differences in Platelet GPIIb-IIIa Activation , 1997, Thrombosis and Haemostasis.

[10]  D. Wennberg,et al.  Differences in outcomes between women and men associated with percutaneous transluminal coronary angioplasty. A regional prospective study of 13,061 procedures. Northern New England Cardiovascular Disease Study Group. , 1996, Circulation.

[11]  R. Fox,et al.  Refining the treatment of women with unstable angina—A randomized, double‐blind, comparative safety and efficacy evaluation of integrelin™ versus aspirin in the management of unstable angina , 1996 .

[12]  J. Miller,et al.  Colleges should have a special membership for doctors practising in another specialty , 1996 .

[13]  K. Lee,et al.  Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. , 1996, Circulation.

[14]  H. Mizuma,et al.  Sex and age differences in soluble guanylate cyclase activity in human platelets. , 1995, Life sciences.

[15]  J. Manson,et al.  The primary prevention of coronary heart disease in women. , 1995, The New England journal of medicine.

[16]  W. Weintraub,et al.  Percutaneous transluminal coronary angioplasty in women compared with men. , 1994, Journal of the American College of Cardiology.

[17]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[18]  K. Agarwal.  Modulation of Vasopressin Actions on Human Platelets by Plasma Adenosine and Theophylline: Gender Differences , 1993, Journal of cardiovascular pharmacology.

[19]  S. Kelsey,et al.  Results of percutaneous transluminal coronary angioplasty in women. 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. , 1993, Circulation.

[20]  E. Topol,et al.  Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. , 1992, The American journal of cardiology.

[21]  J. Rock,et al.  The effect of the menstrual cycle and of decompression stress on arachidonic acid-induced platelet aggregation and on intrinsic platelet thromboxane production in women compared with men. , 1991, American journal of obstetrics and gynecology.

[22]  A. Jaffe,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. , 1988, Journal of the American College of Cardiology.

[23]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[24]  H. W. Reading,et al.  Age and sex differences related to platelet aggregation [proceedings]. , 1980, Biochemical Society transactions.

[25]  P. Ramwell,et al.  Sex and age differences in human platelet aggregation , 1975, Nature.